EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HIV by administration of beta-D-2, 3-didehydro-2,3-dideoxy-5-fluorocytidine



Treatment of HIV by administration of beta-D-2, 3-didehydro-2,3-dideoxy-5-fluorocytidine



Official Gazette of the United States Patent & Trademark Office Patents 1246(3), May 15



A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2',3'-dideoxy-2',3'-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3'-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5' or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

(PDF 0-2 workdays service: $29.90)

Accession: 035980454

Download citation: RISBibTeXText



Related references

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Design and synthesis of 2,3-dideoxy-2,3-didehydro-beta-L-cytidine and 2,3-dideoxy-2,3-didehydro-beta-L-5-fluorocytidine , two exceptionally potent inhibitors of human hepatitis B virus and potent inhibitors of human immunodeficiency virus in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in rhesus monkeys. Antiviral Research 37(3): A47, March, 1998

Preclinical pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in woodchucks. Pharmaceutical Research (New York) 14(11 SUPPL ): S73, 1997

Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine. Antimicrobial Agents and ChemoTherapy 42(7): 1805-1810, 1998

Anti-hepatitis B virus action and metabolism of 2-3-dideoxy-2,3-didehydro-beta-L -5-fluorocytidine. Proceedings of the American Association for Cancer Research Annual Meeting 39: 602, March, 1998

Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrobial Agents and ChemoTherapy 43(2): 381-384, 1999

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset). Antiviral Chemistry & ChemoTherapy 14(1): 49-59, 2003

Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrobial Agents and ChemoTherapy 42(7): 1799-1804, 1998

2,3-Dideoxy-2,3-didehydro-beta-L-5-fluorocytidine exhibits a more potent antiviral effect than lamivudine in chronically WHV infected woodchucks. Hepatology 30(4 PART 2): 344A, 1999

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrobial Agents and ChemoTherapy 44(1): 111-122, 1999

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrobial Agents and ChemoTherapy 45(4): 1065-1077, 2001

Pre-clinical pharmacology of beta-L-2,3-dideoxy-5-fluorocytidine and its prodrug bis- SATE-beta-L-2,3-dideoxy-5-fluorocytidine monophosphate. Antiviral Research 37(3): A64, March, 1998

In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrobial Agents and ChemoTherapy 49(9): 3930-3932, 2005